Nicotine Pouches and Your Gut: What the Research Actually Measured

Search “pouch” alongside almost any bathroom word and the results are not a hospital or a health service. They are quit-tracking apps, a Swedish retailer, and a wet-wipes brand. Three of those apps maintain separate pages for constipation and for the opposite problem, which is a decent proxy for how often the question gets typed. Meanwhile the pages that carry real authority on nicotine pouches — the CDC’s, the American Cancer Society’s, MD Anderson’s — between them say nothing about the bowel at all.

So the question is live and the answer is scattered. It is also, unusually for a wellness topic, a question with actual laboratory measurements behind it — just not the ones being quoted.

The scaleA category that got very large, quietly

The context matters because it explains why this question is suddenly everywhere. Philip Morris International reported 794 million cans of ZYN shipped in the United States in 2025, with fourth-quarter volume up 19 percent year over year and pouch shipments across the Americas up 37 percent. Regulatory footing shifted too: the FDA authorised 20 ZYN products in January 2025 after a scientific review, and then on 30 June 2026 went further, granting modified-risk orders that let those products carry a specific claim: using them instead of cigarettes puts you at lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis.

Two things about that authorisation are worth holding onto, because they are routinely flattened in both directions. The FDA’s own language in 2025 was that authorisation “does not mean these tobacco products are safe, nor are they ‘FDA approved’” — and the 2026 claim is explicitly comparative, measured against cigarettes rather than against nothing. Neither the 2025 review nor the 2026 orders assessed anything about digestion. Among young people the category is smaller than the discourse suggests but not static: CDC’s 2024 National Youth Tobacco Survey put current pouch use at 2.4 percent of high-school students, about 360,000 of them, and 3.9 percent of high-school boys — enough to make pouches the second most-used tobacco product among students that year.

The mechanismNicotine has a measured effect on how fast the colon moves

This is the part the affiliate pages assert and never source. It is measurable, and it has been measured. In a study of healthy non-smoking volunteers, researchers tracked radio-opaque markers through the gut with and without nicotine patches. Whole-gut transit ran 42.6 hours at baseline, 32.2 hours on a 17.5 milligram patch and 28.2 hours on a 35 milligram patch. Almost the entire effect sat in the rectosigmoid — the final stretch before the rectum — where time dropped from 18.6 hours to 7.6.

The dose-dependence is not a footnote, and it is where most internet summaries go wrong. When researchers gave nicotine intravenously to 30 healthy volunteers and 13 people with ulcerative colitis, only the high dose accelerated colonic transit and produced the strong propagating contractions that move stool along. The low dose — deliberately set to mimic a transdermal patch — reduced the colon’s compliance and did not change motor function in the colitis group at all. So “nicotine speeds up your colon” is too flat. “Nicotine changes colonic motor activity, and how much depends on how much” is the honest version.

For scale against a pouch rather than a patch: pharmacokinetic testing found a 6 milligram pouch delivers roughly 3.5 milligrams of nicotine, about 59 percent of what is in it, and a 2025 study in 20 smokers clocked blood nicotine peaking around 30 minutes in, against 6 minutes for a cigarette. Slower to arrive, and a different curve.

The detour worth knowingIt was once tried as a treatment

Here is the fact that reframes the whole topic, and it has been sitting in the New England Journal of Medicine since 1994. Because ulcerative colitis is markedly less common in smokers — one of the stranger observations in gastroenterology — researchers ran a randomised, double-blind trial of transdermal nicotine in 72 people with active ulcerative colitis, on top of their existing medication. Complete remission at six weeks: 17 of 35 on nicotine against 9 of 37 on placebo. Fewer stools per day, less urgency, better appearance on biopsy. Side effects were also more common on nicotine — 23 against 11 — mostly nausea and lightheadedness.

Nicotine never became a colitis treatment; the side-effect profile and better options saw to that. But the trial settles the question of whether nicotine does anything to the large bowel. It does, measurably enough to beat a placebo in a controlled trial, in a journal that does not publish on vibes. That is a much firmer footing than the phrase “gut health” usually rests on.

The number everyone quotesEighty percent, and what it is worth

If you have seen a statistic attached to this topic, it is probably this one. A 2025 cross-sectional study of 1,214 nicotine pouch users in Saudi Arabia found 80.8 percent reported at least one gastrointestinal symptom: bloating 66.7 percent, nausea 47.9, heartburn 46.7, stomach pain 46.5, constipation 45.3, diarrhoea 36.6.

Now the parts that rarely travel with it. It is an online survey circulated through social media and pouch-user communities — people who already had something to say about pouches were the ones answering. There is no control group, so there is no way to know what 1,214 people who do not use pouches would have reported over the same period, and bloating is common enough in the general population that this matters enormously. The sample was 99.4 percent male and 94.5 percent used 10 milligram pouches, which is a strong dose by the standards of what is sold in the US. And the finding that ought to give the biggest pause: there was no dose-response. Frequent users, regular users and occasional users reported symptoms at statistically indistinguishable rates — around 81 percent each, p = 0.844. When a real physiological effect is at work, more exposure usually means more effect; here it did not. The authors say plainly that their findings “do not imply direct effects.”

None of that makes the number worthless. It makes it a description of what a large group of committed users say they experience, which is genuinely interesting, rather than a measurement of what pouches do to a body. Those are different claims, and only one of them has a transit study behind it.

The other directionWhat the research on stopping actually shows

There is no study of what happens to the bowel when someone stops using pouches specifically. There is a good one on stopping tobacco, and the mechanism is the same molecule leaving. Researchers followed 1,067 people through a stop-smoking clinic, rating constipation before the quit date and weekly afterwards. It rose significantly after quitting, peaked at around two weeks, and was still elevated at four. Net, about 17 percent were affected — roughly one in six — and 9 percent went from no constipation at all to describing themselves as very or extremely constipated. The rise was smaller among people using nicotine replacement, which is itself a clue about what is driving it.

Read alongside the transit data, that is a coherent story rather than two unrelated findings: a stimulus that was shortening the last leg of the journey is withdrawn, and the journey lengthens again. It also suggests the effect is temporary and has a shape — worst around a fortnight, easing after — which is more useful to know in advance than to discover.

The open questionNobody can tell you what the pouch is made of

One genuinely unresolved thread, reported in July 2026 by The Examination in partnership with STAT. A former FDA toxicologist, Christy Leppanen — who worked at the agency’s Center for Tobacco Products from 2021 and led a project on microplastics exposure — says the agency authorised ZYN without establishing what the pouch itself is made from, and declined to ask. Philip Morris describes the material as “cellulose, or plant fiber.” The only testing the reporters located was by Denmark’s environmental agency, which examined 11 brands and characterised the material as a semi-synthetic cellulose closely resembling cellulose acetate — the stuff of cigarette filters. The FDA declined three times to say. Its own March 2025 assessment states that it does not address the potential effects of plastics and microplastics from the pouch materials.

The gut connection is the reason a toxicologist cared: microplastics, Leppanen notes, can cross into the bloodstream from the gut, which is why she wanted the material identified before authorisation. But the honest end of that thread is her own: nothing has been published on microplastics from nicotine pouches. No one has measured whether a pouch sheds anything, in a mouth or anywhere else. Other researchers quoted in the piece say only that pouches could shed microplastics if the material is what it appears to be. That is an open question worth following, and it is not a finding — and anyone presenting it to you as one is getting ahead of the evidence.

The ledgerWhat holds up

Sorting it, then. Nicotine has a measured, dose-dependent effect on colonic transit, concentrated in the final stretch of colon, demonstrated with markers in healthy volunteers and firm enough that transdermal nicotine outperformed placebo in a controlled ulcerative colitis trial. Stopping nicotine appears to swing it the other way for a few weeks, peaking around two, based on good cessation data from tobacco. The 80 percent figure describes what a self-selected group of heavy users reports, showed no dose-response, and should not be carried around as a fact about pouches. What the pouch material does, if anything, is unmeasured.

The practical read is unglamorous. A change in bowel habit that lines up with starting or stopping nicotine has a plausible mechanism behind it, which is a reasonably reassuring thing to know when something changes and you are trying to work out why. What that mechanism cannot do is explain away a change that persists, or one that arrives with bleeding, pain, or unexplained weight loss — those belong with a clinician regardless of what else is going on, and quitting support belongs with one too. If you want a sense of where your own pattern sits against the population data, our frequency checker lays out what the studies actually measured. This article is educational, reports what the cited research found, and is not medical advice.